News Releases

November 5, 2026
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device
November 5, 2026
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device
October 29, 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels